Introduction {#s1}
============

Prader--Willi syndrome (PWS) is a genomic imprinting disorder caused by deficiency of paternally expressed gene or genes in the chromosome 15q11-13 region \[[@B1]--[@B4]\]. Most patients are caused by a paternal deletion on the chromosome 15q11--q13 (70%-75%) and a maternal uniparental disomy (mUPD) of chromosome 15 (25%-29%). The imprinting center defect is found in less than 1% of PWS cases. The estimated prevalence of PWS is 1:10,000 to 1:30,000 \[[@B5]--[@B7]\]. The clinical features of PWS include neonatal hypotonia, feeding difficulty, respiratory problem at birth, hypogonadism, cognitive disabilities, hyperphagia, childhood onset obesity, obsessive and compulsive behaviors, and psychiatric illness in adult \[[@B8],[@B9]\]. The diagnostic criteria for the Prader--Willi syndrome (PWS) developed in 1993 have proven to be a useful tool in clinic setting \[[@B10]\]. However, the confirmation of clinical diagnosis usually relies on the molecular genetic testing.

Although the majority of clinical features of PWS are well recognized and characterized, the behavioral features associated with PWS has not been fully investigated. The number of new PWS cases, caused by either paternal deletion of 15q11-q13 or mUPD, has been increased significantly in recent years due to available array CGH (comparative genomic hybridization) technique in clinical diagnostic laboratory. The different clinical presentations related to behaviors and mental health have been suggested between individuals with paternal deletion of 15q11-q13 and mUPD \[[@B11]--[@B13]\]. These differences appear more prominent in the domains of the neurodevelopment and psychiatric presentations. Individuals with mUPD are more likely to have psychosis \[[@B14],[@B15]\], autism spectrum disorders \[[@B16]--[@B19]\], and milder intellectual disability than other causes \[[@B20]--[@B22]\]. Individuals with paternal deletion of 15q11-q13 showed a higher frequency of impaired speech articulation and language development \[[@B23]\].

There is, however, no consensus as to whether the difference in the neurodevelopment outcomes between 15q11-q13 paternal deletion and mUPD are evident and clinically significantly. This information, however, is important to counsel family and develop anticipatory care. Therefore, we reviewed published literature on this topic systematically and conducted a meta-analysis to evaluate the level of intellectual disability and frequency of psychiatric illness and their correlations between PWS cases caused by the 15q11-q13 paternal deletion and mUPD.

Methods {#s2}
=======

Literature Search {#s2.1}
-----------------

A comprehensive literature search was performed to identify the relevant studies in PubMed, the Cochrane Central Register of Controlled Trials and EMBASE from 1956 to May 31, 2012. Using Medical Subject Headings terms, searches were limited to original studies in human. The keyword of Prader--Willi syndrome was used in combination with deletion or UPD.

Study Selection and Data Extraction {#s2.2}
-----------------------------------

The Endnote X4 and NoteExpress2 software were used to compile the data for meta-analysis. The PWS cases confirmed molecularly with either paternal deletion or mUPD were included for meta-analysis. We contacted corresponding authors of the studies for additional information as needed. The studies reported more than one of the outcomes of neurodevelopment were included in the metaanalysis: 1) IQ: full scale IQ (FSIQ), verbal IQ (VIQ) and performance IQ (PIQ); 2) psychiatric illness including depressive psychosis, bipolar disorder or other psychotic illness. The studies were excluded for meta-analysis if required data were incomplete. Two reviewers independently screened all studies for those requiring further retrieval (full text or abstract), and then independently reviewed these studies to identify whether they met the inclusion criteria. Disagreements regarding trial eligibility were discussed and resolved by two reviewers.

Statistical Analysis {#s2.3}
--------------------

We report outcomes using odds rate (OR) with 95% confidence intervals (CIs) for dichotomous data and weighted mean difference (MD) with 95% CI for continuous data. *I* ^2^ statistics were used to measure heterogeneity of the studies. If the *I* ^2^ value was less than 50%, a fixed effects meta-analysis was applied. If the *I* ^2^ value was more than 50%, the random-effects meta-analysis was performed. Potential publication bias was investigated by visual assessment of the funnel plot (plots of effect estimates against sample size). Metaanalyses and funnel plot calculation were performed using Review Manager software version 5.1 (Nordic Cochrane Centre, Copenhagen, Denmark). Statistical significance was determined if the 2-sided P value was less than 0.05.

Results {#s3}
=======

Search Results and Study Characteristics {#s3.1}
----------------------------------------

A total of 581 records were identified from the electronic database, 331 records from PubMed, 250 records from EMBASE. Seventy-seven reviews, 24 animal studies, and 71 single case reports were immediately removed. A total of 22 articles were removed due to language barrier and 131 articles without Prader-willi in their title were removed. Ninety three studies were duplicated in two databases. One hundred fifty studies did not meet the inclusion criteria or because of incomplete data in the papers. After these careful filtering, a total of 13 studies \[[@B11],[@B19],[@B21],[@B24]--[@B33]\] met the inclusion criteria of the meta-analyses. Flow chart of articles screening is presented in [Figure 1](#pone-0072640-g001){ref-type="fig"}. There are 744 PWS cases in 13 studies. Among them, 423 PWS patients with 15q11-q13 paternal deletion (56.9%), 318 with mUPD (42.7%), 3 with imprinting center defect. The distribution of three molecular defects is consistent with other studies in general but with a slightly higher percentage of mUPD \[[@B34]\]. The characteristics of included studies are available in [Table 1](#tab1){ref-type="table"}. Six studies \[[@B11],[@B21],[@B27],[@B30],[@B32],[@B33]\] were carried out in the USA, four \[[@B26],[@B28],[@B29],[@B31]\] in the UK, two \[[@B24],[@B25]\] in Netherlands, one \[[@B19]\] in Belgium. Of the studies included in the systematic review, 11 studies \[[@B11],[@B19],[@B21],[@B26]--[@B33]\] reported IQ score ([Table 2](#tab2){ref-type="table"}), 5 of these studies \[[@B21],[@B26],[@B27],[@B29],[@B30]\] were using the Wechsler Intelligence Scale, 1 study \[[@B11]\] was using the K-BIT scale, 1 study \[[@B28]\] was using Wechsler and Raren's, 1 study \[[@B33]\] was using Kaufman or Wechsler, and 3 studies \[[@B19],[@B31],[@B32]\] did not provide detail description for tools used. Five studies \[[@B11],[@B24]--[@B26],[@B31]\] reported psychiatric illness: 3 studies \[[@B24],[@B26],[@B31]\] used the ICD-10 criteria for the diagnosis and 2 studies \[[@B11],[@B25]\] used psychiatric diagnosis in medical records. The clinical diagnosis in all cases were confirmed by molecular genetic testing using DNA methylation analysis, fluorescence in situ hybridization (FISH), DNA microsatellite analysis or multiplex ligation-dependent probe amplification (MLPA). In 3 studies \[[@B11],[@B27],[@B30]\], the paternal deletions of 15q11-q13 are further divided into class I and class II deletion II based on the genomic locations of breakpoints as previously described \[[@B30],[@B35]\]. Weighted average method was used to combine the IQ scores of the two deletion subgroups.

![Flow chart of articles screening and selection process.](pone.0072640.g001){#pone-0072640-g001}

###### Descriptive characteristics of the included studies.

  Author                            Year    Country of study     Case Number    Male    Deletion    mUPD    Age (y) M[+]{.ul}SD (Range)     PWS diagnosis                                                      Outcome
  --------------------------------- ------- -------------------- -------------- ------- ----------- ------- ------------------------------- ------------------------------------------------------------------ ----------------
  Sinnema et al. \[[@B24]\]         2011    Netherlands          97             NA      53          44      36.2[+]{.ul}12.4 (18-66)        MLPA                                                               Psychiatry
  Mass et al. \[[@B25]\]            2010    Netherlands          79             34      45          33      34.4[+]{.ul}11.8 (18-65)        DNA methylation studies on the SNURF/SNRPN locus                   Psychiatry
  Dykens et al. \[[@B11]\]          2008    USA                  88             43      55          33      22.41[+]{.ul}11.74 (5-51)       FISH, methylation studies, or MLPA/MS-MLPA                         Psychiatry, IQ
  Soni et al. \[[@B26]\]            2008    UK                   46             21      24          22      31.2[+]{.ul}9.6 (12-51)         microsatellite analysis                                            Psychiatry, IQ
  Zarcone et al. \[[@B27]\]         2007    USA                  73             20      42          31      22.7[+]{.ul}9.4 (10-40)         FISH and DNA microsatellite analysis                               IQ
  Descheemaeker et al. \[[@B19]\]   2006    Belgium              59             31      40          18      21.2 (2-51)                     chromosome examination and DNA methylation                         IQ
  Milner et al. \[[@B28]\]          2005    UK                   96             51      47          49      16.3[+]{.ul}12.4 (3.3-50)       quantitative fluorescent PCR assay, microsatellite analysis        IQ
  Walley et al. \[[@B29]\]          2005    UK                   18             11      12          6       23.5[+]{.ul}7.8 (16-49)         molecular genetic testing, no detail                               IQ
  Bulter et al. \[[@B30]\]          2004    USA                  46             21      25          21      23[+]{.ul}8.6                   FISH, methylation and microsatellite analysis                      IQ
  Boer et al. \[[@B31]\]            2002    UK                   15             8       9           5       38.5[+]{.ul}5.7 (29-47)         methylation pattern                                                Psychiatry, IQ
  FOX et al. \[[@B32]\]             2001    USA                  43             NA      24          19      23.3[+]{.ul}8.7                 FISH, methylation and microsatellite analysis                      IQ
  Roof et al. \[[@B21]\]            2000    USA                  38             16      24          14      22.2[+]{.ul}9.1 (10-44)         high-resolution chromosome analysis, DNA microsatellite analysis   IQ
  Dykens et al. \[[@B33]\]          1999    USA                  46             18      23          23      17[+]{.ul}9.42 (6-42)           molecular genetic testing, no detail                               IQ

Note: MLPA, multiplex ligation-dependent probe amplification; FISH, fluorescence in situ hybridization; NA: not available.

###### Characteristics of the IQ reported studies.

  Author                 Year   Diagnostic criteria    Perform                                                                      FSIQ                  VIQ                   PIQ                                                               
  ---------------------- ------ ---------------------- ---------------------------------------------------------------------------- --------------------- --------------------- --------------------- --------------------- --------------------- ---------------------
  Dykens et al.          2008   K-BIT2                 NA                                                                           62.07, 12.3 (n=55)    64.96, 13.07 (n=33)   \-                    \-                    \-                    \-
  Soni et al.            2008   Wechsler               carry out by the first author                                                64.5,8.5 (n=24)       68.7,11.2 (n=22)      \-                    \-                    \-                    \-
  Zarcone et al.         2007   Wechsler               Trained research staff conducted IQ test                                     62.3, 55.1 (n=41)     65.2, 12.1 (n=30)     63.3, 9.3 (n=41)      71.3, 11.9 (n=30)     65.7, 9.3 (n=41)      63.1, 11.3 (n=30)
  Descheemaeker et al.   2006   NA                     NA                                                                           57.2, 16.21 (n=40)    58.4, 15.56 (n=18)    \-                    \-                    \-                    \-
  Milner et al.          2005   Wechsler and Raven's   the researchers involved were blind to the genetic status of participants.   70.78, 16.21 (n=45)   69.49, 16.89 (n=47)   81.16, 17.4 (n=19)    79.62, 21.08 (n=21)   76.53, 14.43 (n=19)   68.57, 10.44 (n=21)
  Walley et al.          2005   Wechsler               NA                                                                           \-                    \-                    71.64, 12.08 (n=12)   76.50, 8.64 (n=6)     \-                    \-
  Bulter et al.          2004   Wechsler               NA                                                                           \-                    \-                    62.52, 9.18 (n=25)    70, 6.20 (n=21)       \-                    \-
  Boer et al.            2002   NA                     NA                                                                           67.0, 12.39 (n=9)     62.4, 9.86 (n=5)      \-                    \-                    \-                    \-
  Fox et al.             2001   NA                     NA                                                                           62.7, 9.8 (n=24)      63.9, 6.4 (n=19)      62.1, 9.5 (n=24)      69.7, 5.5 (n=19)      66.5, 9.6 (n=24)      61.6, 7.7 (n=19)
  Roof et al.            2000   Wechsler               carry on by a licensed psychological examiner                                61, 9.2 (n=24)        64.1, 7.9 (n=14)      60.8, 8.6 (n=24)      69.9, 6.4 (n=14)      64.7, 9.3 (n=24)      62.2, 9.7 (n=14)
  Dykens et al.          1999   Kaufman or Wechsler    two of the university clinics                                                62.97, 8.83 (n=23)    70.93, 11.15 (n=23)   \-                    \-                    \-                    \-

NA: not available

Results of Meta-analysis {#s3.2}
------------------------

### FSIQ in the paternal deletion and mUPD subgroup {#s3.2.1}

Funnel plot for publication bias about FSIQ is presented in [Figure 2](#pone-0072640-g002){ref-type="fig"}. Nine studies \[[@B11],[@B19],[@B21],[@B26]--[@B28],[@B31]--[@B33]\] provided FSIQ scores of PWS patients with 15q11-q13 paternal deletion or mUPD. These studies encompassed 285 cases with the paternal deletion and 211 cases with mUPD. Compared with two molecular groups, the PWS cases with deletion have statistically significant lower FSIQ scores than that of mUPD \[MD =-2.69 (95% confidence interval (CI), -4.86 to -0.52; *p*=0.02)\] and results were homogeneously distributed (*p*=0.57) ([Figure 3](#pone-0072640-g003){ref-type="fig"}).

![Funnel plot for publication bias about FSIQ.](pone.0072640.g002){#pone-0072640-g002}

![Meta analysis of the FSIQ in DEL and UPD groups.](pone.0072640.g003){#pone-0072640-g003}

### VIQ in paternal deletion and mUPD subgroups {#s3.2.2}

Six studies \[[@B21],[@B27]--[@B30],[@B32]\] provided VIQ scores of PWS patients with 15q11-q13 paternal deletion or mUPD. These studies included 145 cases with paternal deletion and 111 cases with mUPD. Compared these subgroups, the PWS cases with deletion showed statistically significant lower VIQ scores than that of mUPD \[MD=-7.50 (95% CI, -9.75 to -5.26; *p*\<0.00001)\] and results were homogeneously distributed (*p*=0.71) ([Figure 4](#pone-0072640-g004){ref-type="fig"}).

![Meta analysis of the VIQ in DEL and UPD groups.](pone.0072640.g004){#pone-0072640-g004}

### PIQ in paternal deletion and mUPD subgroups {#s3.2.3}

Four studies \[[@B21],[@B27],[@B28],[@B32]\] provided PIQ scores for PWS patients with 15q11-q13 paternal deletion or mUPD. These studies encompassed 108 cases with the paternal deletion and 84 cases with mUPD. Compared with these two subgroups, those with paternal deletion showed statistically significant higher PIQ scores than that of mUPD, \[MD=4.02 (95% CI, 1.13 to 6.91; *p*=0.006)\] and results were homogeneously distributed (*p*=0.66) ([Figure 5](#pone-0072640-g005){ref-type="fig"}).

![Meta analysis of the PIQ in DEL and UPD groups.](pone.0072640.g005){#pone-0072640-g005}

### Psychosis in paternal deletion and mUPD subgroups {#s3.2.4}

Funnel plot for publication bias about psychiatric illness is presented in [Figure 6](#pone-0072640-g006){ref-type="fig"}. Five studies \[[@B11],[@B24]--[@B26],[@B31]\] reported prevalence of psychosis in PWS patients with 15q11-q13 paternal deletion or mUPD. These studies encompassed 186 cases with the paternal deletion and 137 cases with mUPD. Compared with the two subtypes, individuals with mUPD were statistically significant more susceptible to psychotic disorder than those with deletion, \[OR=0.14 (95% CI, 0.08 to 0.23; *p*\<0.00001)\] and results were homogeneously distributed (*p*=0.41) ([Figure 7](#pone-0072640-g007){ref-type="fig"}).

![Funnel plot for publication bias about psychosis.](pone.0072640.g006){#pone-0072640-g006}

![Metaanalysis of the prevalence of psychosis in DEL and UPD groups.](pone.0072640.g007){#pone-0072640-g007}

### Depressive psychosis in paternal deletion and mUPD subgroups {#s3.2.5}

Two studies \[[@B24],[@B26]\] reported prevalence of depressive psychosis in PWS patients with 15q11-q13 paternal deletion or mUPD. These studies encompassed 77 cases with the paternal deletion and 66 cases with mUPD. The frequency of depressive psychosis between the genetic subtypes were not statistically significant \[OR=0.77 (95% CI, 0.35 to 1.68; *p*=0.51)\] and results were homogeneously distributed (*p*=0.13) ([Figure 8](#pone-0072640-g008){ref-type="fig"}).

![Metaanalysis of the prevalence of depression in DEL and UPD groups.](pone.0072640.g008){#pone-0072640-g008}

### Bipolar disorder in paternal deletion and mUPD subgroups {#s3.2.6}

Two studies \[[@B24],[@B26]\] reported prevalence of bipolar illness in PWS patients with 15q11-q13 paternal deletion or mUPD. These studies encompassed 77 cases with the paternal deletion and 66 cases with mUPD. Compared with the two genetic subsets, individuals with mUPD were statistically significant more susceptible to bipolar illness than those with deletion, \[OR=0.04 (95% CI, 0.01 to 0.23; *p*=0.0002)\] and results were homogeneously distributed (*p*=0.52) ([Figure 9](#pone-0072640-g009){ref-type="fig"}).

![Metaanalysis of the prevalence of bipolar in DEL and UPD groups.](pone.0072640.g009){#pone-0072640-g009}

Discussion {#s4}
==========

To our knowledge, this is the first meta-analysis to review the psychiatric illness and intellectual abilities in PWS with different types of molecular defects. Our analysis indicates significant differences of clinical presentation related to the neurodevelopment and psychiatric illness between PWS cases with 15q11-q13 paternal deletion and mUPD. Overall, the PWS with paternal deletion have lower FSIQ score than that of mUPD. More specifically, the verbal IQ but not performance IQ is more affected in the cases with 15q11-q13 deletion. Conversely, the psychosis and bipolar disorders are significantly more prevalent in PWS cases with mUPD than that of 15q11-q13 deletion. These findings not only strengthen the previous impression from small scale studies but also provide new insight that has not reported before.

The immediate question is what contributes to these differences between cases with paternal deletion and mUPD. Human chromosome 15q11--q13 is a domain subject to regulation of genomic imprinting, an epigenetic process in which the expression of genes is depending upon the parent-of-origin \[[@B36]\]. It is well known that PWS primarily arises from the deficiency of paternally expressed gene or genes in the 15q11-q13 region. However, it remains a question of debate which genes or genes are responsible for the full spectrum of PWS phenotypes. Three recent reports from analysis of 3 PWS cases have revealed small but overlapping microdeletions including the *SNORD116* snoRNA cluster \[[@B37]--[@B39]\]. These cases have typical clinical features of PWS. However, the neurobehavioral studies have not been evaluated or described in detail. These data support that the paternally expressed *SNORD116* cluster plays a major role in the core features of PWS. However, how the loss of expression non-coding snoRNAs ultimately leads to the clinical presentations of PWS remains unclear. The molecular difference between paternal deletion and mUPD is clear. Summary of the genetic and expression of chromosomal region 15q11, 2-13 are presented in [Table 3](#tab3){ref-type="table"}. In the cases of paternal deletion, the paternally expressed genes in the 15q11-q13 region are predicted to be completely deficient. The maternally expressed genes such as *UBE3A* and *ATP10A* are not affected. The non-imprinted genes in the regions are haploinsufficient in paternal deletion cases. In the mUPD cases, the maternally expressed genes are predicted to be two folds of that in paternal deletion cases and one fold higher than that in normal. The non-imprinted genes are not affected. The expression of imprinted gene is expected to be same as paternal deletion cases if the imprinting is complete or 100%. It is reasonable to hypothesize that the differential expression of genes between paternal deletion of 15q11-q13 and mUPD may contribute to the difference in neurocognitive function and prevalence of psychiatric illness. For instance, the higher expression of *UBE3A* in mUPD cases may play a significant role in psychiatric illness. *UBE3A* is a maternal and brain-specific imprinting gene in the region \[[@B40],[@B41]\]. *UBE3A* encodes ubiquitin protein ligase E3A, functions as an E3 ligase in the ubiquitin proteasome pathway and as a transcriptional coactivator \[[@B42]\]. Loss of function of maternal *UBE3A* causes Angelman syndrome, a neurodevelopmental disorder with intellectual disability, hypotonia and seizures \[[@B43],[@B44]\]. The maternal duplication of 15q11-q13 is one of the most common copy number variants found in autism spectrum disorder \[[@B45]\]. It has been suggested that the *UBE3A* may be the major player to contribute the ASD in these cases \[[@B46],[@B47]\]. Other gene such as *CYFIP1* in the 15q11.2 region may also play a role in contributing to neurodevelopment and psychiatric illness because of copy number variant of 15q11.2 including *CYFIP1* has been associated with schizophrenia \[[@B48]\]. *CYFIP1* encodes cytoplasmic *FMR1* interacting protein 1, and component of the CYFIP1**-**EIF4E-FMR1 complex which binds to the mRNA cap and mediates translational repression \[[@B49]\].

###### Summary of the genetic and expression of chromosomal region 15q11, 2-13.

  **Gene name **   **Description**                                      **Imprinting status**        **Expression level (Deletion)  **   **Expression level (mUPD)  **   **Comparison in two subtypes**
  ---------------- ---------------------------------------------------- ---------------------------- ----------------------------------- ------------------------------- --------------------------------
  TUBGCP5          tubulin, gamma complex associated protein 5          non-imprinted                haploinsufficiency                  normal                          different
  CYFIP1           cytoplasmic FMR1 interacting protein 1               non-imprinted                haploinsufficiency                  normal                          different
  NIPA2            non imprinted in Prader-Willi/Angelman syndrome 2    non-imprinted                haploinsufficiency                  normal                          different
  NIPA1            non imprinted in Prader-Willi/Angelman syndrome 1    non-imprinted                haploinsufficiency                  normal                          different
  GOLGA8E          golgin A8 family, member E, pseudogene               non-imprinted                haploinsufficiency                  normal                          different
  MKRN3            makorin ring finger protein 3                        paternally expressed         no expression                       no expression                   same
  MAGEL2           MAGE-like 2                                          paternally expressed         no expression                       no expression                   same
  NDN              necdin, melanoma antigen (MAGE) family member        paternally expressed         no expression                       no expression                   same
  NPAP1            nuclear pore associated protein 1                    non-imprinted                haploinsufficiency                  normal                          different
  SNRPN            small nuclear ribonucleoprotein polypeptide N        paternally expressed         no expression                       no expression                   same
  SNURF            SNRPN upstream reading frame                         paternally expressed         no expression                       no expression                   same
  snoRNAs          small nucleolar RNA                                  paternally expressed         no expression                       no expression                   same
  UBE3A            ubiquitin protein ligase E3A                         maternally expressed         normal                              over expression                 different
  ATP10A           ATPase, class V, type 10A                            maternally expressed         normal                              over expression                 different
  GABRB3           gamma-aminobutyric acid (GABA) A receptor, beta 3    paternal biased expression   haploinsufficiency                  haploinsufficiency              same
  GABRA5           gamma-aminobutyric acid (GABA) A receptor, alpha 5   paternal biased expression   haploinsufficiency                  haploinsufficiency              same
  GABRG3           gamma-aminobutyric acid (GABA) A receptor, gamma 3   non-imprinted                haploinsufficiency                  normal                          different
  OCA2             oculocutaneous albinism II                           non-imprinted                haploinsufficiency                  normal                          different
  GOLGA8G          golgin A8 family, member G                           non-imprinted                haploinsufficiency                  normal                          different

The clinical implication of our finding is significant because it provides a basis to develop evidence based practice guideline for evaluating and managing individuals with PWS. In particular, our findings provide evidence to support more diligent care of PWS with psychiatric illness.

Our conclusion from the meta-analysis is convincing and significant. However, several imitations in our study may still be worth for discussion and for improvement in future. First, like all other meta-analysis, because clinic data were collected from different investigators, at different sites, and at different ages, the comparison may be confounded by the variable quality of clinical data. Second, it should be noted that the diagnosis of psychiatric diseases in many reports included in meta-analysis might be made based on self-report but not through a specialized clinical evaluation using DSM IV criteria. These limitations may influence the data quality thereby affect the conclusion. Therefore, more accurate and detailed description about psychiatric symptoms is recommended for further study of PWS to figure out underlying molecular mechanism. Third, although the total number of patients is reasonable, the increase of the sample size may still be desirable in future study. Fourth, the breakpoints for the deletion case are not defined in detail.

Conclusion {#s5}
==========

Our meta-analysis has revealed significant differences in the severity of neurocognitive impairment and the prevalence of psychiatric illness between PWS cases with paternal deletion of 15q11-q13 and mUPD. The PWS with paternal deletion have lower FSIQ and VIQ score than that of mUPD, but PWS with mUPD are more susceptible to psychosis, bipolar disorders than that of paternal deletion. These findings may provide a framework for future study to elucidate the genetic basis of psychiatric illness. Our finding will also provide rationale to develop evidence based practice for evaluating and caring individuals with PWS.
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